These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24236927)

  • 1. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains.
    Hamidi A; Bakker WA
    Pharm Pat Anal; 2012 Nov; 1(5):589-99. PubMed ID: 24236927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
    Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
    Verdijk P; Rots NY; Bakker WA
    Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
    Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
    Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of inactivated poliovirus vaccine from Sabin strains: A progress report.
    Okayasu H; Sein C; Hamidi A; Bakker WA; Sutter RW
    Biologicals; 2016 Nov; 44(6):581-587. PubMed ID: 27720268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Universal use of inactivated poliovirus vaccine--the needs and challenges].
    Shimizu H; Takeda N
    Nihon Rinsho; 2008 Oct; 66(10):1950-5. PubMed ID: 18939495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
    Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines.
    Westdijk J; Brugmans D; Martin J; van't Oever A; Bakker WA; Levels L; Kersten G
    Vaccine; 2011 Apr; 29(18):3390-7. PubMed ID: 21397718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.
    Sanders BP; Edo-Matas D; Custers JH; Koldijk MH; Klaren V; Turk M; Luitjens A; Bakker WA; Uytdehaag F; Goudsmit J; Lewis JA; Schuitemaker H
    Vaccine; 2013 Jan; 31(5):850-6. PubMed ID: 23123018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technology transfer of Sabin-IPV to new developing country markets.
    Kreeftenberg H; van der Velden T; Kersten G; van der Heuvel N; de Bruijn M
    Biologicals; 2006 Jun; 34(2):155-8. PubMed ID: 16650773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between vaccine coverage against polio and circulation and genetic evolution of the poliovirus strains isolated in Romania in the framework of the global polio eradication strategy.
    Băicuş A; Persu A; Popescu M; Penciu A; Stavri S; Soare A; Grecu N; Szmal C; Oprişan G
    Roum Arch Microbiol Immunol; 2009; 68(3):145-50. PubMed ID: 20361534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.